GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LadRx Corp (STU:CX5) » Definitions » Cyclically Adjusted PB Ratio

LadRx (STU:CX5) Cyclically Adjusted PB Ratio : 0.01 (As of May. 16, 2024)


View and export this data going back to 1986. Start your Free Trial

What is LadRx Cyclically Adjusted PB Ratio?

As of today (2024-05-16), LadRx's current share price is €0.056. LadRx's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was €10.02. LadRx's Cyclically Adjusted PB Ratio for today is 0.01.

The historical rank and industry rank for LadRx's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:CX5' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.27   Max: 5.21
Current: 0.01

During the past years, LadRx's highest Cyclically Adjusted PB Ratio was 5.21. The lowest was 0.01. And the median was 0.27.

STU:CX5's Cyclically Adjusted PB Ratio is ranked better than
99.85% of 646 companies
in the Biotechnology industry
Industry Median: 1.76 vs STU:CX5: 0.01

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

LadRx's adjusted book value per share data for the three months ended in Dec. 2023 was €0.198. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €10.02 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


LadRx Cyclically Adjusted PB Ratio Historical Data

The historical data trend for LadRx's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LadRx Cyclically Adjusted PB Ratio Chart

LadRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.49 0.18 0.04 0.01

LadRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.03 0.01 0.01 0.01

Competitive Comparison of LadRx's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, LadRx's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LadRx's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LadRx's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where LadRx's Cyclically Adjusted PB Ratio falls into.



LadRx Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

LadRx's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.056/10.02
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LadRx's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, LadRx's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.198/129.4194*129.4194
=0.198

Current CPI (Dec. 2023) = 129.4194.

LadRx Quarterly Data

Book Value per Share CPI Adj_Book
201403 760.547 99.695 987.312
201406 656.094 100.560 844.389
201409 651.052 100.428 838.998
201412 593.044 99.070 774.721
201503 515.096 99.621 669.170
201506 404.946 100.684 520.519
201509 510.776 100.392 658.465
201512 365.208 99.792 473.633
201603 271.722 100.470 350.015
201606 182.448 101.688 232.203
201609 130.123 101.861 165.328
201612 123.952 101.863 157.484
201703 69.283 102.862 87.171
201706 67.004 103.349 83.906
201709 65.189 104.136 81.017
201712 54.686 104.011 68.045
201803 61.474 105.290 75.562
201806 64.151 106.317 78.091
201809 56.942 106.507 69.192
201812 53.208 105.998 64.965
201903 50.375 107.251 60.788
201906 47.586 108.070 56.987
201909 45.434 108.329 54.279
201912 40.683 108.420 48.563
202003 37.987 108.902 45.144
202006 33.959 108.767 40.407
202009 23.775 109.815 28.019
202012 19.989 109.897 23.540
202103 17.481 111.754 20.244
202106 14.655 114.631 16.546
202109 21.813 115.734 24.392
202112 1.720 117.630 1.892
202203 2.645 121.301 2.822
202206 1.976 125.017 2.046
202209 -0.691 125.227 -0.714
202212 -2.762 125.222 -2.855
202303 -3.623 127.348 -3.682
202306 3.321 128.729 3.339
202309 1.826 129.860 1.820
202312 0.198 129.419 0.198

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


LadRx  (STU:CX5) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


LadRx Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of LadRx's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


LadRx (STU:CX5) Business Description

Industry
Traded in Other Exchanges
Address
11726 San Vicente Boulevard, Suite 650, Los Angeles, CA, USA, 90049
LadRx Corp operates as a biopharmaceutical research and development company in the healthcare sector of the United States. It is focused on the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company develops Aldoxorubicin, which is meant to cure soft tissue sarcoma, a kind of tumor. It also develops Arimoclomol which is in development in Niemann Pick disease Type C (NPC) and Gaucher disease.

LadRx (STU:CX5) Headlines

No Headlines